The IV Latin American Congress on Biomedical Engineering, CLAIB2007, corresponds to the triennial congress for the Regional Bioengineering Council for Latin America (CORAL), it is supported by the International Federation for Medical and Biological Engineering (IFMBE) and the Engineering in Medicine, Biology Society (IEEE-EMBS). This time the Venezuela Society of Bioengineering (SOVEB) organized the conference, with the slogan Bioengineering solution for Latin America health.

The IV Latin American Congress on Biomedical Engineering, CLAIB2007, corresponds to the triennial congress for the Regional Bioengineering Council for Latin America (CORAL), it is supported by the International Federation for Medical and Biological Engineering (IFMBE) and the Engineering in Medicine, Biology Society (IEEE-EMBS). This time the Venezuela Society of Bioengineering (SOVEB) organized the conference, with the slogan Bioengineering solution for Latin America health.

The IV Latin American Congress on Biomedical Engineering, CLAIB2007, corresponds to the triennial congress for the Regional Bioengineering Council for Latin America (CORAL), it is supported by the International Federation for Medical and Biological Engineering (IFMBE) and the Engineering in Medicine, Biology Society (IEEE-EMBS). This time the Venezuela Society of Bioengineering (SOVEB) organized the conference, with the slogan Bioengineering solution for Latin America health.

This book contains the summaries of the "Innovation in Pharmacy: Advances and Perspectives" that took place in Salamanca (Spain) in September 2018. The early science of chemistry and microbiology were the source of most drugs until the revolution of genetic engineering in the mid 1970s. Then biotechnology made available novel protein agents such as interferons, blood factors and monoclonal antibodies that have changed the modern pharmacy. Over the past year, a new pharmacy of oligonucleotides has emerged from the science of gene expression such as RNA splicing and RNA interference. The ability to design therapeutic agents from genomic sequences will transform treatment for many diseases. The science that created this advance and its future promise will be discussed. Phillip Allen Sharp is an American geneticist and molecular biologist who co-discovered RNA splicing. He shared the 1993 Nobel Prize in Physiology or Medicine with Richard J. Roberts for “the discovery that genes in eukaryotes are not contiguous strings but contain introns, and that the splicing of messenger RNA to delete those introns can occur in different ways, yielding different proteins from the same DNA sequence. He works in Institute Professor Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA, US. Este libro recoge los resúmenes de la «Innovation in Pharmacy: Advances and Perspectives» que tuvo lugar en Salamanca (España) en septiembre de 2018. La ciencia primitiva de la química y la microbiología fue la fuente de la mayoría de las drogas hasta la revolución de la ingeniería genética a mediados de la década de 1970. Luego, la biotecnología puso a disposición agentes proteínicos novedosos como interferones, factores sanguíneos y anticuerpos monoclonales que han cambiado la farmacia moderna. Durante el año pasado, surgió una nueva farmacia de oligonucleótidos a partir de la ciencia de la expresión génica, como el empalme de ARN y la interferencia de ARN. La capacidad de diseñar agentes terapéuticos a partir de secuencias genómicas transformará el tratamiento de muchas enfermedades. La ciencia que creó este avance y su promesa futura será discutida. Phillip Allen Sharp es un genetista y biólogo molecular estadounidense que co-descubrió el empalme de ARN. Compartió el Premio Nobel de 1993 en Fisiología o Medicina con Richard J. Roberts por "el descubrimiento de que los genes en eucariotas no son cadenas contiguas, sino que contienen intrones, y que el empalme del ARN mensajero para eliminar esos intrones puede ocurrir de diferentes maneras, produciendo diferentes proteínas de la misma secuencia de ADN. Trabaja en el Instituto Profesor Koch Institute for Integrative Cancer Research, Instituto Tecnológico de Massachusetts (MIT), Cambridge, MA, EE. UU.

This volume presents the contributions of the third International Conference on Advancements of Medicine and Health Care through Technology (Meditech 2014), held in in Cluj-Napoka, Romania. The papers of this Proceedings volume present new developments in - Health Care Technology, - Medical Devices, Measurement and Instrumentation, - Medical Imaging, Image and Signal Processing, - Modeling and Simulation, - Molecular Bioengineering, - Biomechanics.

Clinical Cases in Dental Hygiene is an indispensable resource to understanding both the theory and practice of dental hygiene, illustrated by real-life cases in a clinically relevant format. Offers a unique case-based format that supports problem-based learning Promotes independent learning through self-assessment and critical thinking Includes a wealth of relevant cases for understanding dental procedures and management of patients Covers all essential topics within the scope of dental hygiene

Fungi are an understudied, biotechnologically valuable group of organisms. Due to their immense range of habitats, and the consequent need to compete against a diverse array of other fungi, bacteria, and animals, fungi have developed numerous survival mechanisms. However, besides their major basic positive role in the cycling of minerals, organic matter and mobilizing insoluble nutrients, fungi have other beneficial impacts: they are considered good sources of food and active agents for a number of industrial processes involving fermentation mechanisms as in the bread, wine and beer industry. A number of fungi also produce biologically important metabolites such as enzymes, vitamins, antibiotics and several products of important pharmaceutical use; still others are involved in the production of single cell proteins. The economic value of these marked positive activities has been estimated as approximating to trillions of US dollars. The unique attributes of fungi thus herald great promise for their application in biotechnology and industry. Since ancient Egyptians mentioned in their medical prescriptions how they can use green molds in curing wounds as the obvious historical uses of penicillin, fungi can be grown with relative ease, making production at scale viable. The search for fungal biodiversity, and the construction of a living fungi collection, both have incredible economic potential in locating organisms with novel industrial uses that will lead to novel products. Fungi have provided the world with penicillin, lovastatin, and other globally significant medicines, and they remain an untapped resource with enormous industrial potential. Volume 1 of Industrially Important Fungi for Sustainable Development provides an overview to understanding fungal diversity from diverse habitats and their industrial application for future sustainability. It encompasses current advanced knowledge of fungal communities and their potential biotechnological applications in industry and allied sectors. The book will be useful to scientists, researchers, and students of microbiology, biotechnology, agriculture, molecular biology, and environmental biology.